Chimeric Therapeutics Ltd
CHM
Company Profile
Business description
Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.
Contact
62 Lygon Street
Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
stocks
Best and worst performing ASX sectors of 2024
Exploring the ASX sectors that moved the market this year.
stocks
2 ASX companies with the traits of a long-term winner
Two companies that show promising signs of handsomely rewarding shareholders.
video
Our outlook for 2025
Morningstar Equity Market Strategist Lochlan Halloway discusses his view on what we can expect in markets in 2025.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,508.10 | 36.60 | 0.43% |
| CAC 40 | 7,282.69 | 10.37 | 0.14% |
| DAX 40 | 19,848.77 | 35.98 | -0.18% |
| Dow JONES (US) | 43,325.80 | 28.77 | 0.07% |
| FTSE 100 | 8,136.99 | 34.27 | 0.42% |
| HKSE | 20,153.09 | 54.80 | 0.27% |
| NASDAQ | 20,020.36 | 10.77 | -0.05% |
| Nikkei 225 | 40,276.13 | 708.07 | 1.79% |
| NZX 50 Index | 13,205.10 | 130.36 | 1.00% |
| S&P 500 | 6,037.59 | 2.45 | -0.04% |
| S&P/ASX 200 | 8,250.70 | 29.80 | 0.36% |
| SSE Composite Index | 3,408.39 | 10.32 | 0.30% |